We dream big by thinking small, at the cellular level, inventing ways to destroy cancer and advance humanity.

Reimagining cell therapy

Powered by our novel D-Domain technology and paired with our transformative ddCAR and ARC-SparX platforms, our unique approach to cell therapy aims to supercharge how the world treats cancer.

Our Technology

with every cell of our being

From the very beginning, our team has been united to destroy cancer and challenge convention—while ensuring patients stay at the forefront.

Our Company

Mission-critical collaboration

Every day, we are building a more purposeful, empathetic team ready to work together to spearhead change and transform the fight against cancer. Join us.

Culture & Careers

Our Pipeline

Scientific Publications

Latest News

Arcellx Provides First Quarter Financial Results

Arcellx to Participate at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference

Arcellx Provides Fourth Quarter and Year-End 2022 Financial Results and Business Highlights

Arcellx to Participate at the H.C. Wainwright Cell Therapy Virtual Conference

Arcellx to Participate in Upcoming Investor Conferences

Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma

Arcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress

Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma

Arcellx Reports Third Quarter 2022 Financial Results and Business Progress

Arcellx Announces Presentation of New Clinical Data from Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 64th ASH Annual Meeting and Exposition

Arcellx Announces Participation at the Morgan Stanley 20th Annual Global Healthcare Conference

Arcellx Provides Business Highlights and Reports Second Quarter 2022 Financial Results

Arcellx Announces Appointment of Maryam Abdul-Kareem as General Counsel

Arcellx Announces Closing of Upsized Public Offering of Common Stock and Underwriters' Full Exercise of Option to Purchase Additional Shares

Arcellx Announces Upsizing and Pricing of Follow-On Public Offering

Arcellx Presents Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 2022 ASCO Annual Meeting

Arcellx Appoints Michelle Gilson as Chief Financial Officer

Arcellx Appoints Olivia Ware to Board of Directors

Arcellx Provides Business Updates and Reports First Quarter 2022 Financial Results

Arcellx Announces Dosing of First Patient in its Phase 1 Clinical Trial Evaluating ACLX-001, the First Therapeutic in the Dosable and Controllable ARC-SparX Platform, for the treatment of Patients with Relapsed or Refractory Multiple Myeloma

Arcellx Announces Publication in Blood Advances of Clinical Results from the Dose Escalation Cohorts of its CART-ddBCMA Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma

Arcellx Announces Participation at the BofA Securities 2022 Healthcare Conference

Arcellx to Present New Clinical Data from its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma in an Oral Abstract Session at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Arcellx Presents Pre-Clinical Data for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Cancer Research Annual Meeting

Arcellx Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results

Arcellx Announces Participation at the Barclays Global Healthcare Conference

Arcellx Announces Pre-Clinical Data Presentation for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Cancer Research Annual Meeting 2022

Arcellx Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

Arcellx Announces Pricing of Initial Public Offering

Arcellx Presents Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 63rd ASH Annual Meeting and Exposition

Arcellx to Present New Clinical Data from its CART-ddBCMA Phase 1 Trial in Patients with Relapsed and Refractory Multiple Myeloma at the 63rd ASH Annual Meeting and Exposition

Arcellx Announces Presentation of Positive Clinical Results from Ongoing Phase 1 Study of CART-ddBCMA at the 2021 ASCO Annual Meeting

Arcellx to Present Data from Phase 1 Study of CART-ddBCMA Demonstrating Continued Positive Response in Patients with Relapsed and Refractory Multiple Myeloma at the 2021 ASCO Annual Meeting

Preclinical Data of Arcellx’s Novel Synthetic CAR-T Binding Domain Presented at the 2021 ASGCT Annual Meeting and the 2021 PEGS Summit

Arcellx Announces Executive Appointments

Arcellx Closes $115 Million Series C Financing to Advance its Pipeline of Adaptive and Controllable Cell Therapies

Arcellx Announces FDA Clearance of IND Application for ACLX-001, a Controllable Cell Therapy Utilizing the Company’s ARC-SparX Platform, for the Treatment of Multiple Myeloma

Arcellx Appoints Rami Elghandour as Chairman and Chief Executive Officer

Arcellx CART-ddBCMA Cell Therapy Demonstrates Deep and Durable Responses in the Treatment of Relapsed and Refractory Multiple Myeloma

Arcellx Announces Clinical Data to be Presented at the 62nd American Society of Hematology (ASH) Annual Meeting

Arcellx to Present at Jefferies Virtual Cell Therapy Summit

Arcellx Announces EvansMDS Grant Awarded for Collaboration with Johns Hopkins and University of Colorado Researchers to Support Development of Arcellx ARC-sparX Platform Candidate ACLX-002

BioBuzz: Martha Sklavos, PhD, PMP Joins Arcellx as new Senior Director, Program Management

Arcellx Presents Preclinical Data for ARC-sparX Platform Technology in Targeting CD123-Positive AML Tumors

Arcellx to Present at Jefferies Virtual Healthcare Conference

Arcellx to Present at the UBS Virtual Global Healthcare Conference

Arcellx to Present Preclinical Data of its Novel ARC-sparX Platform Technology in Targeting HER2+ Solid Tumors at the 2020 American Society of Clinical Oncology Virtual Annual Meeting

Arcellx to Present Preclinical Efficacy Data of the ARC-sparX Platform Technology at the 2020 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Arcellx Announces FDA Orphan Drug Designation for CART-ddBCMA for the Treatment of Multiple Myeloma

Arcellx Announces First Patient Treated with T Cell Therapy Utilizing the Company’s Novel Binding Domain

Arcellx Announces Close of $85M Series B to Fund Early-Stage Clinical Trials and Advance Pipeline of ARC-T/sparX Therapies

Contact Us

Sign up for updates

Stay at the forefront of our advancements
in the battle against cancer.

*First Name

*Last Name

*Email Address

Message (Optional)

*Required field

By clicking SUBMIT, you agree to our Terms & Conditions and Privacy Policy, and to receive information from Arcellx, its affiliates, service providers, and co-promotion partners.